Di Lauro L, Fattoruso Lorsque, Giacinti L, et al. Second-line chemo with FOLFIRI inside patients having metastatic gastric malignant tumors (MGC) maybe not previously given fluoropyrimidines. J Clin Oncol. 2009. s (suppl; abstr 4549).
Burtness B, Gibson M, Egleston B, ainsi que al. Phase II demo off docetaxel-irinotecan combination in the cutting-edge esophageal cancer tumors. Ann Oncol. 2009 Jul. 20(7):1242-8. [QxMD MEDLINE Link].
A stage II trial comparing capecitabine and you can irinotecan as second line medication in customers having oesophago-gastric cancer tumors that have changed for the, or inside 90 days out of platinum-situated chemo
Catenacci DVT, Kang YK, Playground H, et al. Margetuximab also pembrolizumab inside people with in the past managed, HER2-confident gastro-oesophageal adenocarcinoma (CP-MGAH22-05): an individual-case, stage 1b-2 demo. Lancet Oncol. 2020 Aug. 21 (8):1066-1076. [QxMD MEDLINE Hook up]. [Complete Text message].
Doebele Rc, Drilon A good, Paz-Ares L, Siena S, et al. Entrectinib when you look at the patients with state-of-the-art mylol visitors otherwise metastatic NTRK combo-self-confident solid tumours: included study out-of three phase step 1-dos examples. Lancet Oncol. 2020 Feb. 21 (2):271-282. [QxMD MEDLINE Hook up]. [Full Text].
Drilon An excellent, Laetsch TW, Kummar S, DuBois SG, mais aussi al. Efficacy regarding Larotrectinib into the TRK Collection-Self-confident Cancer tumors for the Adults and children. N Engl J Med. 2018 Feb 22. 378 (8):731-739. [QxMD MEDLINE Link]. [Full Text message].
Le DT, Durham JN, Smith KN, mais aussi al. Mismatch resolve lack forecasts effect regarding strong cancers in order to PD-1 blockade. Research. 2017 Jul 28. 357 (6349):409-413. [QxMD MEDLINE Hook up].
Ce DT, Uram JN, Wang H, ainsi que al. PD-step one Blockade in Tumors with Mismatch-Resolve Deficiency. N Engl J Med. 2015 Jun twenty five. 372 (26):2509-20. [QxMD MEDLINE Hook up].
You. Sahin, O
Tabernero J, Yoshino T, Cohn AL, Obermanucirumab instead of placebo in conjunction with next-range FOLFIRI during the clients with metastatic colorectal carcinoma that advanced during or once very first-range procedures with bevacizumab, oxaliplatin, and you can a good fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase step three data. Lancet Oncol. 2015 Get. 16 (5):499-508. [QxMD MEDLINE Hook up]. [Full Text message].
Mitani S, Kadowaki S, Komori A beneficial, Kondoh C, Oze We, Kato K, mais aussi al. A phase II Examination of Modified FOLFOX6 to own Complex Gastric Cancer tumors Refractory so you’re able to Important Therapy. Adv Ther. 2020 Jun. 37 (6):2853-2864. [QxMD MEDLINE Connect]. [Full Text].
Shitara K, Doi T, Dvorkin Yards, Mansoor W, Arkenau HT, Prokharau An effective, ainsi que al. Trifluridine/tipiracil versus placebo inside the clients having heavily pretreated metastatic gastric cancer tumors (TAGS): a great randomised, double-blind, placebo-managed, phase step three demo. Lancet Oncol. 2018 The fall of. 19 (11):1437-1448. [QxMD MEDLINE Link].
Kawazoe A great, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, et al. Defense and pastime away from trifluridine/tipiracil and you will ramucirumab in prior to now addressed advanced gastric cancer tumors: an unbarred-term, single-case, phase dos trial. Lancet Gastroenterol Hepatol. 2021 Mar. 6 (3):209-217. [QxMD MEDLINE Hook]. [Full Text].
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, ainsi que al. A phase step 3 examination of nivolumab during the in the past handled complex gastric or gastroesophageal junction cancers (ATTRACTION-2): 2-season up-date analysis. Gastric Cancer tumors. 2020 Get. 23 (3):510-519. [QxMD MEDLINE Connect]. [Full Text].
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A great, Asayama Meters, mais aussi al. Regorafenib Plus Nivolumab when you look at the Customers With State-of-the-art Gastric otherwise Colorectal Cancer: An unbarred-Name, Dose-Escalation, and you will Dose-Extension Phase Ib Demo (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20. 38 (18):2053-2061. [QxMD MEDLINE Hook up]. [Full Text].
Tureci, G. Manikhas, et. al. FAST: a great randomised stage II study of zolbetuximab (IMAB362) as well as EOX instead of EOX by yourself getting earliest-range treatments for complex CLDN18.2-positive gatric and you can gastro-oesophageal adenocarcinoma. Annals out-of Oncology. 2021 Could possibly get. Vol -619. [Complete Text message].
Nivolumab lengthened disease 100 % free emergency during the clients which have resected (R0) phase II or III esophageal or gastroesophageal junction disease which acquired neoadjuvant chemoradiotherapy and had recurring pathological disease.
Docetaxel 70-85 mg/yards dos IV toward big date 1 including cisplatin 70-75 mg/meters dos IV for the go out step one; every 21 d [forty-five, 46, 47] otherwise
Javle MM, Yang G, Nwogu Le, ainsi que al. Capecitabine, oxaliplatin and radiation therapy: a phase IB neoadjuvant studies getting esophageal malignant tumors with gene expression studies. Cancers Purchase. 2009 Feb. 27(2):193-200. [QxMD MEDLINE Link].
Enzinger Pc, Burtness BA, Niedzwiecki D, Ye X, ainsi que al. CALGB 80403 (Alliance)/E1206: A good Randomized Phase II Examination of About three Chemo Routines And Cetuximab for the Metastatic Esophageal and you may Gastroesophageal Aug ten. 34 (23):2736-42. [QxMD MEDLINE Link]. [Complete Text].
Albertsson M, Johansson B, Friesland S, ainsi que al. Stage II knowledge on the docetaxel alone most of the 3rd day, or a week in combination with gemcitabine inside the patients having number one in your town complex, metastatic, otherwise perennial esophageal cancer tumors. Med Oncol. 2007. 24(4):407-twelve. [QxMD MEDLINE Link].
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy to have before managed cutting-edge gastric otherwise gastro-oesophageal junction adenocarcinoma (REGARD): a global, randomised, multicentre, placebo-controlled, stage 3 trial. Lancet. 2014 Jan cuatro. 383(9911):31-nine. [QxMD MEDLINE Link].